GRFS
Companies
NASDAQ
Grifols S.A.
Health Care
$8.70
+$1.34 (+18.08%)
Price Chart
Overview
About GRFS
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.
Market Cap
$4.9B
Volume
10.3M
Avg. Volume
11.8M
P/E Ratio
6.017857
Dividend Yield
14.07%
Employees
16.9K
Company Information
Risk & Correlation Analysis
Market Correlation
1.63
High Correlation
Volatility
High (0.56)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Low Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Low Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, GRFS shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$4.9B
Volume10.3M
P/E Ratio6.02
Dividend Yield14.07%
Important Dates
Next Dividend
June 14, 2021Next Earnings
February 26, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025